Passenger Business Achieves Profitability
Blade's passenger business reached positive segment adjusted EBITDA in the trailing 12-month period ending September 30, 2024, more than a year ahead of previous guidance.
Significant Margin Expansion
Passenger and Medical segments drove a 27.3% year-over-year increase in flight profit, with adjusted EBITDA of $4.2 million growing fivefold from the prior year.
Strategic Alliance with OrganOx
Blade announced a strategic partnership with OrganOx to enhance the availability of Metra perfusion devices, aimed at increasing the utilization of donor organs.
Medical Segment Growth
Medical segment adjusted EBITDA improved by 15.1% in Q3 2024, with a significant rebound in activity reported for October, achieving one of the highest monthly revenue levels in company history.
Strong Cash Flow Generation
Generated $6.4 million in operating cash flow and $3.7 million in free cash flow before aircraft acquisitions in the quarter.